Wcn24-1837 Beyond: A Phase 3, Randomized, Double-Blind, Placebocontrolled Trial of Zigakibart in Adults With Iga Nephropathy

IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis and has limited treatment options. Zigakibart (BION-1301) is a novel, humanized monoclonal antibody that blocks APRIL (a proliferation-inducing ligand), a cytokine that is elevated in patients with IgAN. APRIL promotes the production of pathogenic galactose-deficient IgA1 (Gd-IgA1), resulting in immune complex formation and glomerular deposition, causing inflammation and kidney injury. Blocking APRIL with zigakibart is a potential disease-modifying approach to treating IgAN.